$0.15
(Market cap
$55 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-13 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
17,269,400
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Renovacor (RCOR)
| -58.4 | 4.6 | 67.5 | -62.8 | -- | -- | -- |
|
BSE Sensex*
| -10.2 | -0.9 | -7.6 | -7.0 | 7.1 | 8.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Renovacor (RCOR)
| -24.5 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Renovacor (RCOR)
Renovacor, Inc., a biotechnology company, focuses on delivering various precision therapies to enhance the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. It primarily focuses on the... treatment of BCL2-associated athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy (DCM). The company's lead product candidate is REN-001, a recombinant adeno-associated virus 9-based gene therapy designed to deliver a functional BAG3 gene to augment BAG3 protein levels in cardiomyocytes, and slow or halt progression of BAG3 DCM. It is also developing a pipeline of BAG3-associated gene therapies for diseases with high unmet medical need associated with mutations in the BAG3 gene and mechanistically linked to BAG3's expression and function. The company was founded in 2013 and is based in Greenwich, Connecticut. Read more
-
Chairman, Pres & CEO
Dr. Magdalene K. Cook M.D.
-
Chief Scientific Officer
Dr. Matthew Killeen Ph.D.
-
Headquarters
Greenwich, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Renovacor (RCOR)
What is the current share price of Renovacor Inc (RCOR) Today?
The share price of Renovacor Inc (RCOR) is $3.20 (NYSE) as of 30-Nov-2022 16:00 EDT. Renovacor Inc (RCOR) has given a return of -62.79% in the last 1 years.
What is the current PB & PE ratio of Renovacor Inc (RCOR)?
Since, TTM earnings of Renovacor Inc (RCOR) is negative, P/E ratio is not available.
The P/B ratio of Renovacor Inc (RCOR) is 1.23 times as on 16-Dec-2022, a 76 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-5.46
|
1,438.07
|
|
2020
|
-52.26
|
0.47
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
-5.46
|
1,438.07
|
What is the 52 Week High and Low of Renovacor Inc (RCOR)?
The 52-week high and low of Renovacor Inc (RCOR) are Rs -- and Rs -- as of 26-May-2026.
What is the market cap of Renovacor Inc (RCOR)?
Renovacor Inc (RCOR) has a market capitalisation of $ 55 Mln as on 16-Dec-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Renovacor Inc (RCOR)?
Before investing in Renovacor Inc (RCOR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.